Document:

Exhibit 10.3

 

Execution Version

 

SPONSOR SUPPORT AGREEMENT

 

This Sponsor Support
Agreement (this “Sponsor Agreement”) is dated as of February 9, 2021, by and among CMLS Holdings LLC, a Delaware
limited liability company (the “Sponsor”), CM Life Sciences, Inc., a Delaware corporation (“Parent”),
and Mount Sinai Genomics, Inc., a Delaware corporation, d/b/a Sema4 (the “Company”). Capitalized terms used
but not defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).

 

WHEREAS, as of the
date hereof, Sponsor is the holder of record and the “beneficial owner” (within the meaning of Rule 13d-3 under the
Exchange Act) of 9,987,500 shares of Parent Class B Stock and 6,466,667 Private Placement Warrants (collectively, the “Subject
Securities”);

 

WHEREAS, contemporaneously
with the execution and delivery of this Sponsor Agreement, Parent, S-IV Sub, Inc., a Delaware corporation (“Merger Sub”)
and the Company have entered into an Agreement and Plan of Merger (as amended or modified from time to time, the “Merger
Agreement”), dated as of February 9, 2021, pursuant to which, among other transactions, Merger Sub is to merge with and
into the Company, with the Company continuing on as the surviving entity and a wholly owned subsidiary of Parent, on the terms
and conditions set forth therein; and

 

WHEREAS, as an inducement
to Parent and the Company to enter into the Merger Agreement and to consummate the transactions contemplated therein, the parties
hereto desire to agree to certain matters as set forth herein.

 

NOW, THEREFORE, in
consideration of the foregoing and the mutual agreements contained herein, and intending to be legally bound hereby, the parties
hereto hereby agree as follows:

 

ARTICLE
I

SPONSOR SUPPORT AGREEMENT; COVENANTS

 

Section 1.1
Binding Effect of Merger Agreement. Sponsor hereby acknowledges that it has read the Merger Agreement and this Sponsor
Agreement and has had the opportunity to consult with its tax and legal advisors. The following sections of the Merger Agreement
shall be incorporated into this Sponsor Agreement, mutatis mutanis: Sections 7.10 (No Solicitation) and 7.3(b) (Other
Filings; Press Release) (including any relevant definitions contained in any such Sections), and Sponsor hereby agrees to be
bound by and comply with such sections as though Sponsor was an original signatory to the Merger Agreement with respect to such
sections.

 

Section 1.2
No Transfer. During the period commencing on the date hereof and ending on the earliest of: (a) the Effective Time;
(b) such date and time as the Merger Agreement shall be terminated in accordance with Section 9.1 (Termination) thereof
(the earlier of (a) and (b), the “Expiration Time”); and (c) the liquidation of Parent, Sponsor shall not, without
the prior written consent of the Company, (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option
to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, file (or participate in the filing of) a registration
statement with the SEC (other than the Proxy Statement or the registration statement of the Parent) or establish or increase a
put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act,
with respect to any Sponsor’s Subject Securities (unless the transferee agrees to be bound by this Sponsor Agreement), (ii)
enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of any Sponsor’s Subject Securities or (iii) publicly announce any intention to effect any transaction specified in clause
(i) or (ii).

 

     

     

    

 

Section 1.3
New Shares. In the event that (a) any Parent Shares, Parent Warrants or other equity securities of Parent are issued
to Sponsor after the date of this Sponsor Agreement pursuant to any stock dividend, stock split, recapitalization, reclassification,
combination or exchange of Parent Shares or Parent Warrants of, on or affecting Parent Shares or Parent Warrants owned by Sponsor
or otherwise, (b) a Sponsor purchases or otherwise acquires “beneficial ownership” (within the meaning of Rule 13d-3
under the Exchange Act) of any Parent Shares, Parent Warrants or other equity securities of Parent after the date of this Sponsor
Agreement, or (c) a Sponsor acquires the right to vote or share in the voting of any Parent Shares, Parent Warrants or other equity
securities of Parent after the date of this Sponsor Agreement (such Parent Shares, Parent Warrants or other equity securities of
Parent, collectively the “New Securities”), then such New Securities acquired or purchased by Sponsor shall
be subject to the terms of this Sponsor Agreement to the same extent as if they constituted Sponsor’s Subject Securities
as of the date hereof.

 

Section 1.4
Closing Date Deliverables. At or prior to the Closing, Sponsor shall deliver to Parent and the Company a duly executed
copy of that certain A&R Registration Rights Agreement, by and among, Parent, the Company and the Company Stockholders or their
respective affiliates, as applicable, in substantially the form attached as Exhibit E to the Merger Agreement.

 

Section 1.5
Sponsor Agreements.

 

(a)
At any meeting of the shareholders of Parent, however called, or at any adjournment thereof, or in any other circumstance
in which the vote, consent or other approval of the shareholders of Parent is sought, Sponsor shall (i) appear at each such meeting
or otherwise cause all of Sponsor’s Subject Securities to be counted as present thereat for purposes of calculating a quorum
and (ii) vote (or cause to be voted), or execute and deliver a written consent (or cause a written consent to be executed and delivered)
covering, all of the Sponsor’s Subject Securities:

 

		(i)	in favor of each of the Parent Stockholder Matters;

 

		(ii)	against any business combination, merger agreement or merger
(other than the Merger Agreement, the Merger and proposed Transactions), consolidation, combination, sale of substantial assets,
reorganization, recapitalization, dissolution, liquidation or winding up of or by Parent, including any proposal for any of the
foregoing (other than the Parent Stockholder Matters), regardless of whether there has been a Change in Recommendation;

 

		(iii)	against any proposal that would result in a change in the
business, management or Board of Directors of Parent (other than in connection with the Parent Stockholder Matters as contemplated
by the Merger Agreement); and

 

    2 

     

    

 

		(iv)	against any proposal, action or agreement that would (A)
impede, frustrate, prevent or nullify any provision of this Agreement, the Merger Agreement or Merger, (B) result in a breach
in any respect of any covenant, representation, warranty or any other obligation or agreement of Parent or the Merger Sub under
the Merger Agreement, (C) result in any of the conditions set forth in Article VIII of the Merger Agreement not being fulfilled
or (D) change in any manner the dividend policy or capitalization of, including the voting or other rights of any class of capital
stock of, Parent.

 

Sponsor hereby agrees
that it shall not commit or agree to take any action inconsistent with the foregoing.

 

(b)
Sponsor shall comply with, and fully perform all of its obligations, covenants and agreements set forth in, the Insider
Letter (as defined below), including the obligations of Sponsor therein to not redeem any Parent Shares owned by Sponsor in connection
with the Transactions.

 

(c)
During the period commencing on the date hereof and ending at the Expiration Time, without the prior written consent of
the Company, Sponsor shall not, without the consent of the Company (not to be unreasonably withheld, conditioned or delayed), modify
or amend any Contract listed on Schedule I hereto.

 

Section 1.6
Further Assurances. Sponsor shall take, or cause to be taken, all actions and do, or cause to be done, all things
reasonably necessary under applicable Laws to consummate the Mergers and the other transactions contemplated by the Merger Agreement
on the terms and subject to the conditions set forth therein and herein.

 

Section 1.7
No Inconsistent Agreement. Sponsor hereby represents and covenants that it has not entered into, and shall not enter
into, any agreement that would restrict, limit or interfere with the performance of its obligations hereunder.

 

Section 1.8
No Amendment to the Inside Letter. Neither Sponsor nor Parent shall amend, terminate or otherwise modify that certain
letter agreement, dated as of September 1, 2020, by and among the Parent, Sponsor and certain of the Parent’s current and
former officers and directors (the “Inside Letter” and each party thereto a “Founder Holder”)
without the Company’s prior written consent.

 

Section 1.9
Waiver. Sponsor shall, and shall cause each Founder Holder to, irrevocably and unconditionally waive (the “Waiver”)
any and all rights, title and interest Sponsor or such Founder Holder has or will have under Article 4.3(b) of the Parent Charter
to receive excess shares upon conversion of the shares of Parent Class A Stock in connection with the Merger or the Transactions.

 

    3 

     

    

 

ARTICLE
II

REPRESENTATIONS AND WARRANTIES

 

Section 2.1
Representations and Warranties of Sponsor. Sponsor represents and warrants as of the date hereof to Parent and the
Company as follows:

 

(a)
Organization; Due Authorization. Sponsor is duly organized, validly existing and in good standing under the laws
of the jurisdiction in which it is incorporated, formed, organized or constituted, and the execution, delivery and performance
of this Sponsor Agreement and the consummation of the transactions contemplated hereby are within its corporate limited liability
company or organizational powers and has been duly authorized by all necessary corporate, limited liability company or organizational
actions on the part of Sponsor. This Sponsor Agreement has been duly executed and delivered by Sponsor and, assuming due authorization,
execution and delivery by the other parties to this Sponsor Agreement, this Sponsor Agreement constitutes a legally valid and binding
obligation of Sponsor, enforceable against Sponsor in accordance with the terms hereof (except as enforceability may be limited
by bankruptcy Laws, other similar Laws affecting creditors’ rights and general principles of equity affecting the availability
of specific performance and other equitable remedies). If this Sponsor Agreement is being executed in a representative or fiduciary
capacity, the Person signing this Sponsor Agreement has full power and authority to enter into this Sponsor Agreement on behalf
of Sponsor.

 

(b)
Ownership. Sponsor is the record and “beneficial owner” (within the meaning of Rule 13d-3 under the Exchange
Act) of, and has good title to, Sponsor’s Subject Securities, and there exist no Liens or any other limitation or restriction
(including any restriction on the right to vote, sell or otherwise dispose of such Subject Securities (other than transfer restrictions
under the Securities Act)) affecting any such Subject Securities, other than Liens or any other limitation or restriction pursuant
to (i) this Sponsor Agreement, (ii) the Parent Organizational Documents, (iii) the Merger Agreement, (iv) the Insider Letter and
(v) any applicable securities laws. Sponsor’s Subject Securities are the only equity securities in Parent owned of record
or beneficially by Sponsor on the date of this Sponsor Agreement, and none of Sponsor’s Subject Securities are subject to
any proxy, voting trust or other agreement or arrangement with respect to the voting of such Subject Securities, except as provided
hereunder and under the Insider Letter, Merger Agreement and organizational documents of Sponsor. Other than the warrants of Parent
held by Sponsor, Sponsor does not hold or own any rights to acquire (directly or indirectly) any equity securities of Parent or
any equity securities convertible into, or which can be exchanged for, equity securities of Parent.

 

(c)
No Conflicts. The execution and delivery of this Sponsor Agreement by Sponsor does not, and the performance by Sponsor
of his, her or its obligations hereunder will not, (i) conflict with or result in a violation of the organizational documents of
Sponsor or (ii) require any consent or approval that has not been given or other action that has not been taken by any Person (including
under any Contract binding upon Sponsor or Sponsor’s Subject Securities), in each case, to the extent such consent, approval
or other action would prevent, enjoin or materially delay the performance by Sponsor of its obligations under this Sponsor Agreement.

 

(d)
Litigation. There are no Legal Proceedings pending against Sponsor, or to the knowledge of Sponsor threatened against
Sponsor, before (or, in the case of threatened Legal Proceedings, that would be before) any arbitrator or any Governmental Entity,
which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by Sponsor of its obligations under
this Sponsor Agreement.

 

    4 

     

    

 

(e)
Brokerage Fees. Except as described on Section 5.21 of the Parent Disclosure Letter, no broker, finder, investment
banker or other Person is entitled to any brokerage fee, finders’ fee or other commission in connection with the transactions
contemplated by the Merger Agreement based upon arrangements made by Sponsor, for which Parent or any of its Affiliates may become
liable.

 

(f)  Affiliate Arrangements. Except as set forth on Schedule II hereto or otherwise disclosed in Parent’s Form S-1
Registration Statement filed with the SEC, neither Sponsor nor any of the present or former directors, officers, employees, stockholders
or Affiliates of Sponsor (or an immediate family member of any of the foregoing) is party to, or has any rights with respect to
or arising from, any Contract with Parent.

 

(g)
Acknowledgment. Sponsor understands and acknowledges that each of Parent and the Company is entering into the Merger
Agreement in reliance upon Sponsor’s execution and delivery of this Sponsor Agreement.

 

ARTICLE
III

MISCELLANEOUS

 

Section 3.1
Termination. This Sponsor Agreement and all of its provisions (except for Section 1.8 of this Sponsor Agreement)
shall terminate and be of no further force or effect upon the earliest of: (a) the Expiration Time, (b) the liquidation of Parent
and (c) the written agreement of the Sponsor, Parent, and the Company. Upon such termination of this Sponsor Agreement, all obligations
of the parties under this Sponsor Agreement will terminate, without any liability or other obligation on the part of any party
hereto to any Person in respect hereof or the transactions contemplated hereby, and no party hereto shall have any claim against
another (and no person shall have any rights against such party), whether under contract, tort or otherwise, with respect to the
subject matter hereof; provided, however, that the termination of this Sponsor Agreement shall not relieve any party hereto from
liability arising in respect of any breach of this Sponsor Agreement prior to such termination. This Article III shall survive
the termination of this Sponsor Agreement.

 

Section 3.2
No Responsibility for Parent Related Parties. Notwithstanding anything in this Sponsor Agreement to the contrary,
(i) Sponsor shall not be responsible for the actions of Parent, the board of directors of Parent (or any committee thereof), or
any officers, directors, employees or professional advisors of Parent, in each case acting in their capacity as such (collectively,
the “Parent Related Parties”) and (ii) Sponsor makes no representations or warranties with respect to the actions of
any of the Parent Related Parties.

 

Section 3.3
Governing Law. This Sponsor Agreement, and all claims or causes of action (whether in contract or tort) that may
be based upon, arise out of or relate to this Sponsor Agreement or the negotiation, execution or performance of this Sponsor Agreement
(including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection
with this Sponsor Agreement) will be governed by and construed in accordance with the internal Laws of the State of Delaware applicable
to agreements executed and performed entirely within such State.

 

    5 

     

    

 

Section 3.4
CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER OF JURY TRIAL.

 

(a)
THE PARTIES TO THIS SPONSOR AGREEMENT SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE
(OR, TO THE EXTENT SUCH COURT DOES NOT HAVE SUBJECT MATTER JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE) IN RESPECT
OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS OF THIS SPONSOR AGREEMENT AND ANY RELATED AGREEMENT, CERTIFICATE OR OTHER
DOCUMENT DELIVERED IN CONNECTION HEREWITH AND BY THIS SPONSOR AGREEMENT WAIVE, AND AGREE NOT TO ASSERT, ANY DEFENSE IN ANY ACTION
FOR THE INTERPRETATION OR ENFORCEMENT OF THIS SPONSOR AGREEMENT AND ANY RELATED AGREEMENT, CERTIFICATE OR OTHER DOCUMENT DELIVERED
IN CONNECTION HEREWITH, THAT THEY ARE NOT SUBJECT THERETO OR THAT SUCH ACTION MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SUCH
COURTS OR THAT THIS SPONSOR AGREEMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS OR THAT THEIR PROPERTY IS EXEMPT OR IMMUNE FROM
EXECUTION, THAT THE ACTION IS BROUGHT IN AN INCONVENIENT FORUM, OR THAT THE VENUE OF THE ACTION IS IMPROPER. SERVICE OF PROCESS
WITH RESPECT THERETO MAY BE MADE UPON ANY PARTY TO THIS SPONSOR AGREEMENT BY MAILING A COPY THEREOF BY REGISTERED OR CERTIFIED
MAIL, POSTAGE PREPAID, TO SUCH PARTY AT ITS ADDRESS AS PROVIDED IN Section 3.8.

 

(b)
WAIVER OF TRIAL BY JURY. EACH PARTY HERETO HEREBY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER
THIS SPONSOR AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY
AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY
ARISING OUT OF OR RELATING TO THIS SPONSOR AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS SPONSOR AGREEMENT. EACH PARTY CERTIFIES
AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT
SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH SUCH PARTY UNDERSTANDS
AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH SUCH PARTY
HAS BEEN INDUCED TO ENTER INTO THIS SPONSOR AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS Section
3.8.

 

Section 3.5
Assignment. This Sponsor Agreement and all of the provisions hereof will be binding upon and inure to the benefit
of the parties hereto and their respective heirs, successors and permitted assigns. Neither this Sponsor Agreement nor any of the
rights, interests or obligations hereunder will be assigned (including by operation of law) without the prior written consent of
the parties hereto.

 

    6 

     

    

 

Section 3.6
Specific Performance. The parties hereto agree that irreparable damage may occur in the event that any of the provisions
of this Sponsor Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly
agreed that the parties hereto shall be entitled to enforce specifically the terms and provisions of this Sponsor Agreement in
any court of the United States or any state having jurisdiction and immediate injunctive relief to prevent breaches of this Agreement,
without the necessity of proving the inadequacy of money damages as a remedy and without bond or other security being required,
this being in addition to any other remedy to which they are entitled at law or in equity.

 

Section 3.7
Amendment. This Sponsor Agreement may not be amended, changed, supplemented, waived or otherwise modified or terminated,
except upon the execution and delivery of a written agreement executed by Sponsor, Parent and the Company.

 

Section 3.8
Severability. If any provision of this Sponsor Agreement is held invalid or unenforceable by any court of competent
jurisdiction, the other provisions of this Sponsor Agreement will remain in full force and effect. Any provision of this Sponsor
Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid
or unenforceable.

 

Section 3.9
Notices. All notices and other communications hereunder shall be in writing and shall be deemed given: (a) on the
date established by the sender as having been delivered personally; (b) one (1) Business Day after being sent by a nationally recognized
overnight courier guaranteeing overnight delivery; (c) on the date delivered, if delivered by email, with confirmation of transmission;
or (d) on the fifth (5th) Business Day after the date mailed, by certified or registered mail, return receipt requested,
postage prepaid. Such communications, to be valid, must be addressed as follows:

 

If to Parent or Sponsor:

 

c/o CM Life Sciences, Inc.

667 Madison Avenue

New York, NY 10065

Attention: Eli Casdin

E-mail: eli@casdincapital.com

 

with a copy (which shall not constitute notice) to:

 

White & Case LLP

1221 Avenue of the Americas

New York, NY 10020-1095

Attention:          Joel L. Rubinstein

 Matthew Kautz

 

    7 

     

    

 

Email:         joel.rubinstein@whitecase.com

 mkautz@whitecase.com

 

If to Company:

 

Mount Sinai Genomics, Inc. d/b/a Sema4

333 Ludlow Street

Stamford, Connecticut 06902 Attention: General Counsel

Email: legal@sema4.com

with a copy (which shall not constitute notice) to:

 

Fenwick & West LLP

902 Broadway

New York, NY 10010

Attention: Ethan Skerry, Robert A. Freedman and
David K. Michaels

		Email:	         eskerry@fenwick.com

  rfreedman@fenwick.com

 dmichaels@fenwick.com

 

Section 3.10  Counterparts.
This Sponsor Agreement may be executed in two (2) or more counterparts (any of which may be delivered by electronic
transmission), each of which shall constitute an original, and all of which taken together shall constitute one and the same
instrument.

 

Section 3.11 Trust
Account Waiver. Section 7.7 (No Claim Against Trust Account) of the Merger Agreement is hereby incorporated into this
Sponsor Agreement, mutatis mutandis.

 

Section 3.12 Entire Agreement. This Sponsor Agreement and the agreements referenced herein constitute the entire agreement and
understanding of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements
or representations by or among the parties hereto to the extent they relate in any way to the subject matter hereof.

 

[The remainder of this
page is intentionally left blank.]

 

    8 

     

    

 

IN WITNESS WHEREOF,
Sponsor, Parent, and the Company have each caused this Sponsor Support Agreement to be duly executed as of the date first written
above.

 

 

	 	SPONSOR:
	 	 	 
	 	CMLS Holdings LLC
	 	 	 
	 	By:	/s/ Eli Casdin
	 	 	Name: Eli Casdin
	 	 	Title: Member

 

[Signature Page to Sponsor Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF,
Sponsor, Parent, and the Company have each caused this Sponsor Support Agreement to be duly executed as of the date first written
above.

 

 

	 	PARENT:
	 	 	 
	 	CM Life Sciences, Inc.
	 	 	 
	 	By:	/s/ Eli Casdin 
	 	 	Name: Eli Casdin
	 	 	Title: Chief Executive Officer

 

[Signature Page to Sponsor Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF,
Sponsor, Parent, and the Company have each caused this Sponsor Support Agreement to be duly executed as of the date first written
above.

 

	 	COMPANY:
	 	 	 
	 	Mount Sinai Genomics, Inc.
	 	 	 
	 	By:	/s/ Dr. Eric Schadt
	 	 	Name: Dr. Eric Schadt
	 	 	Title: Chief Executive Officer

 

[Signature Page to Sponsor Support Agreement]

 

     

     

    

 

Schedule I

 

		1.	Warrant Agreement, dated September 1, 2020, by and between CM Life Sciences, Inc. and Continental
Stock Transfer & Trust Company, as warrant agent.

 

[Signature Page to Sponsor Support Agreement]

 

     

     

    

 

Schedule II

 

		●	Arrangement pursuant to which Keith Meister and Eli Casdin paid $12,500 each to White & Case
in connection with the initial formation matters on behalf of CM Life Sciences, Inc.

		●	Purchase Agreements with advised clients of Corvex Mangement LP and Casdin Capital LLC who agree
to purchase Class A common shares under the Forward Purchase Agreement.

 

[Signature Page to Sponsor Support Agreement]Exhibit 10.4

 

Execution Version

 

SPONSOR FORFEITURE AGREEMENT

 

February 9, 2021

 

CMLS Holdings LLC

667 Madison Avenue

New York, NY 10065

 

Mount Sinai Genomics, Inc. (d/b/a Sema4)

333 Ludlow Street

Stamford, CT 06902

 

Re: Forfeiture of Certain Sponsor Class
B Common Stock and Private Placement Warrants

 

Ladies and Gentlemen:

 

Reference is hereby
made to:

 

		(i)	that certain Agreement and Plan of Merger (the “Merger Agreement”), dated
as of the date hereof, among CM Life Sciences, Inc., a Delaware corporation and publicly traded NASDAQ-listed acquisition company
(“Parent”), S-IV Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Parent (“Merger
Sub”), and Mount Sinai Genomics, Inc., a Delaware corporation, d/b/a Sema4 (the “Company”);

 

		(ii)	that certain Private Placement Warrants Purchase Agreement (the “Warrant Purchase Agreement”),
dated September 1, 2020, among Parent, CMLS Holdings LLC, a Delaware limited liability company (the “Sponsor”)
and the other parties thereto, pursuant to which the Sponsor and the other purchasers set forth on the signature pages thereto
(the “Purchasers”) acquired redeemable warrants to purchase shares of Parent’s Class A common stock (the
”Sponsor Warrants”), as more specifically set forth therein; and

 

		(iii)	that certain Securities Subscription Agreement (the “Subscription Agreement”),
dated July 16, 2020, between the Sponsor and Parent, pursuant to which the Sponsor subscribed for shares of Class B common stock
of Parent (the “Sponsor Class B Shares”), as more specifically set forth therein.

 

Capitalized terms
used but not defined herein shall have the meanings ascribed to them in the Merger Agreement, the Warrant Purchase Agreement or
the Subscription Agreement, as applicable.

 

In order to induce
Parent and the Company to enter into the Merger Agreement and to proceed with the transactions contemplated therein and thereby,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Parent, the Company
and the Sponsor, hereby agree, pursuant to this letter agreement (this “Letter Agreement”), as follows:

 

		1.	Forfeiture of Sponsor Warrants. Effective immediately prior to (and contingent upon) the
Closing, the Sponsor agrees to forfeit a certain number of the Sponsor Warrants, calculated as follows:

 

		(a)	In the event that Parent Stockholder Redemptions reduce the aggregate amount of funds held in the
Trust Account, the Sponsor agrees to forfeit a number of the Sponsor Warrants equal to the product of:

 

		(i)	one-third (1/3) of the Sponsor Warrants; multiplied by

 

    1 

     

    

 

		(ii)	a percentage equal to the quotient of the dollar amount of Parent Stockholder Redemptions divided
by dollar value of the aggregate amount of funds held in the Trust Account as of the date hereof (the “Forfeiture Percentage”).

 

Such product,
rounded down to the nearest whole number of Sponsor Warrants, the “Forfeited Sponsor Warrants,” and the
forfeiture thereof, the “Warrant Forfeiture.”

 

For the avoidance
of doubt, in no event shall the number of Forfeited Sponsor Warrants be less than zero or greater than one-third (1/3) of the Sponsor
Warrants. Notwithstanding the foregoing, no Warrant Forfeiture will be required if the Forfeiture Percentage is less than 3%.

 

		2.	Forfeiture of Sponsor Class B Shares. Effective immediately prior to (and contingent upon)
the Closing, the Sponsor agrees to forfeit a certain number of the Sponsor Class B Shares, calculated as follows:

 

		(a)	In the event that Parent Stockholder Redemptions reduce the aggregate amount of funds held in the
Trust Account, the Sponsor agrees to forfeit a number of the Sponsor Class B Shares equal to the product of:

 

		(i)	one-third (1/3) of the Sponsor Class B Shares; multiplied by

 

		(ii)	the Forfeiture Percentage.

 

Such product,
rounded down to the nearest whole number of Sponsor Class B Shares, the “Forfeited Sponsor Class B Shares,”
and the forfeiture thereof, the “Share Forfeiture.”

 

For the avoidance
of doubt, in no event shall the number of Forfeited Class B Shares be less than zero or greater than one-third (1/3) of the Sponsor
Class B Shares. Notwithstanding the foregoing, no Share Forfeiture will be required if the Forfeiture Percentage is less than 3%.

 

		3.	To effect the Warrant Forfeiture and the Share Forfeiture (together, the “Forfeitures”),
immediately prior to (and contingent upon) the Closing:

 

		(a)	the Sponsor shall surrender the Forfeited Sponsor Warrants and the Forfeited Sponsor Class B Shares
(together, the “Forfeited Sponsor Securities”) to the Company for cancellation and in exchange for no
consideration;

 

		(b)	the Company shall immediately retire and cancel all of the Forfeited Sponsor Securities (and shall
direct the Company’s transfer agent (or such other intermediaries as appropriate) to take any and all such actions incident
thereto); and

 

		(c)	the Sponsor and the Company each shall take such actions as are necessary to cause the Forfeited
Sponsor Securities to be retired and cancelled, after which the Forfeited Sponsor Securities shall no longer be issued, outstanding,
convertible, or exercisable, and the Sponsor shall provide the Company with evidence that such retirement and cancellation has
occurred.

 

		4.	The Sponsor hereby represents and warrants to the Company, as of the date hereof and as of the
Closing, that the Sponsor owns, and holds of record, all of the Forfeited Sponsor Securities, free and clear of all Liens and other
obligations in respect of the Forfeited Sponsor Securities.

 

		5.	No party hereto may assign either this Letter Agreement or any of its rights, interests, or obligations
hereunder without the prior written consent of each of the other parties hereto. Any purported assignment in violation of this
paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee.
This Letter Agreement shall be binding on the Sponsor, the Company, and their respective successors and assigns.

 

    2 

     

    

 

		6.	Any notice, consent, or request to be given in connection with any of the terms or provisions of
this Letter Agreement shall be in writing and shall be sent by express mail or similar private courier service, by certified mail
(return receipt requested), by hand delivery or facsimile transmission.

 

		7.	This Letter Agreement shall immediately terminate, without any further action by the parties hereto,
at such time, if at all, that the Merger Agreement is terminated in accordance with its terms.

 

		8.	Section 11.3 (Counterparts), Section 11.4 (Entire Agreement), Section 11.5
(Severability), Section 11.7 (Governing Law), Section 11.8 (Consent to Jurisdiction; Waiver of Jury Trial),
Section 11.12 (Amendment), and Section 11.13 (Waiver) of the Merger Agreement are hereby incorporated into
this Letter Agreement, mutatis mutandis, as though set out in their entirety in this paragraph 9.

 

[Signature pages to follow]

 

    3 

     

    

 

In Witness Whereof, this Agreement
has been duly executed and delivered by each Party as of the date first above written.

 

	SPONSOR:	 
	 	 
	CMLS Holdings LLC	 
	 	 
	By:	/s/ Eli Casdin	 
	Name: 	Eli Casdin	 
	Title:	Member	 
	 	 
	COMPANY:	 
	 	 
	Mount Sinai Genomics, Inc.	 
	 	 
	By:	/s/ Eric Schadt	 
	Name:	Dr. Eric Schadt	 
	Title:	Chief Executive Officer	 

 

[Signature Page to Sponsor Forfeiture
Agreement]

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]